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Abstract CRISPR and CRISPR-associated (Cas) pro-
teins, which in nature comprise the RNA-based adaptive
immune system in bacteria and archaea, have emerged as
particularly powerful genome editing tools owing to their
unrivaled ease of use and ability to modify genomes across
mammalian model systems. As such, the CRISPR–Cas9
system holds promise as a ‘‘system of choice’’ for func-
tional mammalian genetic studies across biological disci-
plines. Here we briefly review this fast moving field,
introduce the CRISPR–Cas9 system and its application to
genome editing, with a focus on the basic considerations in
designing the targeting guide RNA sequence.
Introduction
Site-directed DNA endonucleases are powerful tools for
genome editing. When introduced into cells, these proteins
can bind to a target DNA sequence in the genome and
create a DNA double-strand break (DSB), the repair of
which leads to varied DNA sequence modifications. The
initial efforts on developing these tools were focused on
engineering homing endonucleases (Silva et al. 2011) and
zinc finger nucleases (ZFN) (Urnov et al. 2005, 2010), and
later Transcription Activator-Like Effector Nucleases
(TALEN) (Boch et al. 2009; Moscou and Bogdanove 2009;
Bogdanove and Voytas 2011). Homing endonucleases use
one single domain to perform both DNA recognition and
cleavage functions, and as such, are challenging to engi-
neer. For both the ZFN and TALEN systems, the DNA
binding domains (DBD) are modular and can be engi-
neered to recognize and bind specific DNA sequences, al-
lowing an attached nuclease domain to generate DSBs at
the target site. However, for each genomic target, a unique
pair of ZFN or TALEN needs to be designed and gener-
ated, which is cumbersome and time-consuming. In 2012, a
novel system, Clustered Regularly Interspaced Short
Palindromic Repeats (CRISPR) and the CRISPR-associat-
ed proteins (Cas), emerged from the acquired immune
system of bacteria and archaea (Jinek et al. 2012).
CRISPR–Cas9 rapidly became the method of choice for
genome editing having many advantages over the earlier
approaches (Doudna and Charpentier 2014; Hsu et al.
2014). Here we briefly review this fast moving field, in-
troduce the CRISPR–Cas9 system and discuss its applica-
tion to genome editing, with a focus on the basic
considerations in designing the targeting guide RNA
sequence.
CRISPR–Cas9-mediated genome editing
The CRISPR–Cas system was first described in the genome
of Escherichia coli as a cluster of short palindromic repeats
separated by peculiar short spacer sequences (Ishino et al.
1987). Subsequently, it was shown that CRISPR loci are
present in the genomes of more than 40 % of bacteria and
90 % of archaea (Horvath and Barrangou 2010) and their
function is to serve as an adaptive immune defense
mechanism, protecting against phage infection by recog-
nizing and cleaving pathogen DNA (Horvath and
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Barrangou 2010; Fineran and Charpentier 2012). By 2012,
the basic mechanism of CRISPR–Cas9 derived from
Streptococcus pyogenes was elucidated (Deltcheva et al.
2011; Jinek et al. 2012). CRISPR–Cas9 is an RNA-guided
DNA endonuclease system in which Cas9 endonuclease
forms a complex with two naturally occurring RNA spe-
cies, CRISPR RNA (crRNA) and trans activating CRISPR
RNA (tracrRNA). This complex targets specific DNA se-
quences complementary to the 20 nt (nucleotide) sequence
residing at the 50 end of the crRNA (Jinek et al. 2012).
Conveniently, crRNA and tracrRNA can be linked by an
arbitrary stem loop sequence to generate a synthetic single-
guide RNA (sgRNA). Although naturally evolving as a
system in bacteria, upon appropriate codon optimization of
the Cas9 coding sequence, CRISPR–Cas9 is highly active
in mammalian cells (Cho et al. 2013; Cong et al. 2013;
Jinek et al. 2013; Mali et al. 2013b).
In practice, by simply designing the 50 20 nt sequence on
the sgRNA to be complementary to the genomic target
sequence, the Cas9 nuclease-sgRNA complex can be di-
rected to specific genomic locus generating DNA DSBs.
The target defining region of the sgRNA is about 20 nt
long, with variations from 17 to 30 nt having been suc-
cessfully used (Ran et al. 2013; Fu et al. 2014). The other
key element in determining target sequence specificity is
the Protospacer Adjacent Motif (PAM) that is adjacent to
the target site at the genome locus, but is not a part of the
guide RNA sequence (see Fig. 1). For Cas9 nuclease from
S. pyogenes, the PAM sequence is NGG, while CRISPR–
Cas9 systems from other species use different PAM
sequences (Cong et al. 2013; Esvelt et al. 2013; Hou et al.
2013). In bacteria, the PAM is thought to effectively dis-
tinguish self, with the PAM not being present in the ge-
nomic CRISPR loci, from the invading phage, whose
genome carries the PAM sequence adjacent to the target
sequence (Marraffini and Sontheimer 2010).
CRISPR–Cas9-mediated DNA DSBs are repaired
through either the Non-Homologous End Joining (NHEJ)
repair process, or the homology-directed repair (HDR)
pathway. NHEJ repair often leads to small insertions or
deletions (indels) at the targeted site, while HDR pathway
leads to perfect repair or precise genetic modification (see
Fig. 1) (Doudna and Charpentier 2014; Hsu et al. 2014).
Through these two DNA repair pathways, various genetic
modifications can be achieved (Fig. 1). The NHEJ-medi-
ated DNA repair pathway can be exploited to generate null
mutation alleles. Indel mutations generated at a target site
within an exon can lead to frame shift mutations in one or
both alleles. One major advantage of the CRISPR–Cas9
system, as compared to conventional gene targeting and
other programmable endonucleases, is the ease of multi-
plexing, where multiple genes can be mutated simultane-
ously simply by using multiple sgRNAs each targeting a
different gene (Wang et al. 2013a, b). In addition, when
two sgRNAs are used flanking a genomic region, the in-
tervening region can be deleted or inverted (Blasco et al.
2014; Canver et al. 2014; He et al. 2015). Furthermore,
chromosomal translocation can also be achieved by using
two sgRNAs targeting two genomic loci located on dif-
ferent chromosomes (Choi and Meyerson 2014).
Fig. 1 CRISPR–Cas9-mediated
genome editing. a The structure
of Cas9–sgRNA complex
binding to target DNA. Cas9
binds to specific DNA
sequences via the base-pairing
of the guide sequence on
sgRNA (pink) with the DNA
target (gray). Protospacer
adjacent motif (PAM) is
downstream of the target
sequence. b The CRISPR–Cas9-
mediated double-stranded DNA
breaks are repaired by
endogenous DNA repair
machinery: non-homologous
end joining (NHEJ) or
homology-directed repair
(HDR). Various genetic
modifications can be generated
through these two pathways
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When a DSB is generated and a donor DNA template is
provided, precise genetic modification can be introduced
through the HDR pathway (Fig. 1). For small modifica-
tions, including incorporation of point mutations, defined
indel mutations, as well as insertion of a short sequence
such as a loxP site or an epitope tag, single-stranded
oligodeoxynucleotide (ssODN) can be used as donor DNA.
In this design, donor ssODN is designed to carry ho-
mologous sequences flanking the mutation and total size
can be up to 200 nt. HDR efficiency does not appear to be
directly correlated with donor homology lengths (Yang
et al. 2013b), and HDR efficiency variation is likely due to
the nature of the target genomic loci, which is still poorly
understood. When DNA of larger sizes is to be introduced
into a target site, a double-stranded donor plasmid carrying
the transgene flanked by homologous arms is used (Yang
et al. 2013a).
Because of the ease of use, CRISPR–Cas9 system has
swiftly become the most commonly used tool for efficient
genome editing of bacteria, plants, cell lines, primary cells,
and tissues. Impressively, direct introduction of CRISPR–
Cas9 into the zygote leads to efficient genetic modification
of the genome in early embryos, which when brought to
term develop into genetically modified animals (Hwang
et al. 2013; Li et al. 2013a,b; Wang et al. 2013a; Yang et al.
2013a; Hai et al. 2014; Niu et al. 2014). Depending on the
experimental setup, different methods can be used to de-
liver CRISPR–Cas9 system. When used as a genome
editing tool in cultured cells, either electroporation or
transfection is often used to deliver a plasmid containing a
ubiquitous promoter driving Cas9 and sgRNA expression
(Cong et al. 2013; Mali et al. 2013b). The genome editing
efficiency achieved is highly dependent on a number of
variables including the actual transfection efficiency, ge-
nomic locus intended to be targeted, and cell types. For
genetic engineering in animals, Cas9 mRNA or protein and
the sgRNA (with or without donor DNA) are introduced
into zygotes by microinjection (Li et al. 2013a,b; Wang
et al. 2013a; Yang et al. 2013a; Hwang et al. 2013; Hai
et al. 2014; Niu et al. 2014). Germline modification has
also been achieved in mice by transfection of plasmids
expressing Cas9 and sgRNA into spermatogonial stem
cells. After development to spermatids and injection into
oocytes (i.e., fertilization), germline transmission of the
specific genetic modification was achieved (Wu et al.
2015). Lastly, somatic cell genomic modification in mice
has been achieved, by hydrodynamic tail vein injection of
plasmids (Xue et al. 2014; Yin et al. 2014), as well as by
injecting adeno-associated virus (AAV) expressing
CRISPR–Cas9 in brain (Swiech et al. 2015).
The wild-type S. pyogenes-Cas9 (SP-Cas9) endonucle-
ase has two nuclease domains, HNH and RuvC-like, each
capable of cleaving one of the double-stranded target DNA
when associated with a sgRNA (See Fig. 1). When either
one of these domains is mutated, the Cas9-sgRNA complex
becomes a sequence and strand-specific nickase (Cas9n).
When used with two sgRNAs in close proximity and tar-
geting opposite DNA strands, this ‘‘dual’’ Cas9 nickase
generates a DSB with defined overhangs. The more com-
monly used Cas9n is D10A, where the RuvC domain is
mutated and generates 50 overhang (Mali et al. 2013a; Ran
et al. 2013). H840A Cas9n that generates a 30 overhang has
also been successfully applied to mouse model generation
(Shen et al. 2014). Furthermore, when both nuclease do-
mains are mutated eliminating all endonuclease activity,
Cas9 becomes a programmable DNA binding protein
(deadCas9 or dCas9). Guided by sgRNA, dCas9, when
fused with different effector domains such as KRAB do-
main or VP64, can be directed to promoters and directly
influence the level of gene transcription (Cheng et al. 2013;
Gilbert et al. 2013; Konermann et al. 2014). By using
various dCas9-effector fusions, it may be possible to epi-
genetically modify a specific locus leading to change in
gene expression in vitro and in vivo.
In addition to SP-Cas9, several orthologous CRISPR–
Cas9 systems from other species have been characterized
and applied to genome editing in mammalian cells (Cong
et al. 2013; Esvelt et al. 2013; Hou et al. 2013). Compared
to SP CRISPR–Cas9 system, most of these orthologous
systems have different PAM requirements and crRNA and
tracrRNA sequences. Their development and application
will greatly expand the sequence space amendable to
CRISPR–Cas9 targeting. In addition, by recognizing dif-
ferent sgRNA backbones, Cas9 from different species can
be used to perform different functions in the same cells,
without interfering with each other (Esvelt et al. 2013).
These developments will be useful for applications such as
modulation of transcription networks and labeling of
multiple genomic sequences for live cell imaging.
Design of CRISPR/Cas9 guide sequence—
achieving a high targeting efficiency and specificity
Specificity of the CRISPR–Cas9 system is defined by the
20 nt located at the 50 end of the sgRNA, which interacts
with the target DNA by Watson–Crick RNA–DNA base-
pairing. Although highly specific, Cas9-sgRNA binding to
the target DNA can tolerate sequence mismatches, leading
to mutations in unintended genomic loci (‘‘off-target’’ ef-
fect) (Fu et al. 2013; Hsu et al. 2013; Lin et al. 2014). The
principal variables that impact specificity may include
target sequence length and composition, concentrations of
the Cas9 protein and the sgRNA. Although much needs to
be understood to fully define these parameters in a specific
targeting experiment, below we attempt to discuss current
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strategies and available software for the design of the guide
RNA.
Rational design of CRISPR guide sequence aims to
maximize occurrence of the desired genetic modification at
the target site, while minimizing the extent of unintended
mutations at off-target sites. To begin defining parameters
affecting on-target efficiency, recent work investigated the
effect of target sequence composition on targeting efficiency
(Wang et al. 2013b; Doench et al. 2014). Both studies con-
cluded that a high or low GC content in guide sequence leads
to lower efficiency, while other variables may also impact the
efficiency (Wang et al. 2013b; Doench et al. 2014). When a
guide sequence capable of mediating efficient on-target
cleavage has been identified, it should be assessed for po-
tential off-target activities within the genome of interest. As
discussed earlier, CRISPR–Cas9 targeting specificity is de-
termined by a 20 nt guide sequence located at the 50 end of the
sgRNA, plus the PAM sequence adjacent to the target site
located at the genomic locus. Mismatches between the guide
sequence and target DNA are tolerated to certain extent,
especially in the region distal to the PAM sequence (Jinek
et al. 2012; Fu et al. 2013; Hsu et al. 2013). Therefore,
whenever possible, a guide sequence that matches or is
highly similar to multiple genomic loci should be avoided to
prevent off-target effects that may lead to unintended and
often undetected genetic modification in the genome of the
cell or organism. To assist researchers with the design of
CRISPR–Cas9 experiments, a growing number of software
tools have become available for designing guide RNA and
predicting off-target profiles (see Table 1).
Most of the current guide RNA design and off-target pre-
diction tools rely on rules derived from earlier studies based on
simple sequence matches/mismatches (Fu et al. 2013; Hsu et al.
2013) and are focused on optimizing computational time, re-
sources, and providing additional features to assist users to
design the experiment to meet their specific goals. In general,
most of currently available tools allow mismatches of target
sequences up to 3 or 4 nucleotides (Sander et al. 2007,2010;
Hsu et al. 2013; Heigwer et al. 2014), and in a GPU-based
implementation, up to 1–10 mismatches in the online version
and up to any number of mismatches in the standalone version
(Bae et al. 2014b). Recent studies have begun to collect more
experimental data to generate better models for computational
predictions. Using experimentally derived models, ‘‘sgRNA
Designer’’ predicts on-target efficacy using a logistic regres-
sion classifier trained on[1000 sgRNAs targeting multiple
genes and scores sgRNAs using position-specific weights for
nucleotides and dinucleotides (Doench et al. 2014). ‘‘CRISPR
Design Tool’’ incorporates the number of mismatches, position
of mismatches, and pairwise distances of mismatches into its
off-target scoring scheme, which was derived from a set of
systematically designed experiments (Hsu et al. 2013). For
guide RNA designs, some tools allow specification of
experimental goals by users for different desired modifications
(e.g., insertion of tags, disruption of protein domains, etc.) or
allow the use of gene architecture annotation to assist guide
RNA designs (E-CRISP, CHOPCHOP). While most of the
tools are designed for SP-Cas9 with NGG or NAG PAM se-
quences (ZiFiT, CRISPR Design Tool, E-CRISP, sgRNA de-
sign tool), a few provide flexibility for PAM sequences to allow
design of guide RNA for orthogonal Cas9 proteins with dif-
ferent PAM requirements (RGEN Tools, CHOP–CHOP). With
more experiments investigating how parameters such as target
sequence effect on sgRNA expression and folding, as well as
epigenetic context of on-target and off-target sites, we foresee
in the near future better software packages or updates to ex-
isting tools will become available and benefit researchers in the
design of more efficient and specific gene editing experiments.
Strategies for mitigating off-target effect
As eluded above, intelligent design of sgRNA guide se-
quence is still in its infancy. Below, we have listed the
main approaches that can be used in conjunction with
software systems listed in Table 1.
(i) Choose a guide sequence with minimal potential
off-target sites as determined by genome-wide
homology searches. Among the guides, choose
those with off-targets’ mismatches concentrated at
the PAM proximal part of the guide sequence, as
these are less tolerated for Cas9 function (Jinek
et al. 2012; Fu et al. 2013; Hsu et al. 2013).
(ii) Use a guide sequence of shorter lengths (e.g.,
17–19 nt). Fu et al. demonstrated that shorter
targeting sequence in the sgRNAs could reduce
off-target effect significantly with only a slight
reduction of on-target efficiency (Fu et al. 2014).
(iii) Use dual nickase strategy. With a pair of closely
positioned sgRNAs, Cas9 nickase (D10A mutant)
can introduce two adjacent single-stranded nicks,
leading to a DSB with defined overhangs. This
approach has been demonstrated to reduce off-
target activity by 50- to 1500-fold in cell lines and
to achieve gene knockout in mouse zygotes
without sacrificing on-target cleavage efficiency
(Ran et al. 2013; Shen et al. 2014).
(iv) Use dCas9-FokI strategy. Using a pair of sgRNAs
with optimal spacing and orientation, dCas9 fused
with Fok1 nuclease domain can form dimer and
generate DSB, similar to the design of ZFN and
TALEN. The specificity is significantly increased
using this strategy (Guilinger et al. 2014; Tsai
et al. 2014).
(v) Off-target identification and mitigation. In addi-
tion to computational prediction, several strategies
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have been developed to experimentally identify
off-target mutations (Frock et al. 2015; Kim et al.
2015; Tsai et al. 2015; Wang et al. 2015). By
genotyping these potential off-target sites, cell
lines containing desired genetic modification but
free of off-target mutations can be identified. In
the case of animal models, breeding can be used to
segregate the desired allele from the off-target
mutant alleles.
Each of these strategies comes with its own advantages
and limitations. Hence, when designing CRISPR–Cas9
experiments, it is important to understand the potential
impact of unintentional off-target mutations and the need
for mitigating them. For example, if CRISPR–Cas9 is to be
used for clinical intervention, it is essential that off-target
effect be minimized and its potential impacts understood
and/or removed. If, however, the aim is to develop animal
models, it is less of a concern, as founder animals will be
backcrossed and unintended mutant alleles segregated. A
possible simple strategy to avoid misinterpretation of data
due to off-target effect is to develop genetically modified
models using at least two independent sgRNAs with dif-
ferent guide RNA sequences.
Brief outline of CRISPR–Cas9-meditated genome
editing in mouse
To help understand the general process of CRISPR–Cas9-
mediated genome editing, here we outline the basic strat-
egy and considerations for generating mouse models using
CRISPR–Cas9 system (Table 2).
For generating indel-based null allele, single sgRNA
targeting slightly 30 of ATG or the first coding exon shared
by all mRNA isoforms may be a good idea in general.
Small indels generated using a single sgRNA can be either
in-frame or out-frame mutations. The ‘‘RGEN Tools’’ is
designed to analyze sequence surrounding the DSB site for
the likelihood of microhomology-mediated repair (MMR)
and a guide sequence can be chosen to optimize the oc-
currence of frameshift mutations (Bae et al. 2014a).
Knock in models can be divided into two categories
practically. With ‘‘small’’ alterations, the intended muta-
tion, such as incorporation of a point mutation, tag, loxP
site, can be accommodated into a donor ssODN, along with
homology sequences flanking the mutation, for a total size
of 200 nt which is the limit for current ssODN synthesis.
For the larger alterations that could not be accommodated
onto a ssODN, a dsDNA plasmid can be synthesized or
assembled by molecular techniques, with homology arm
lengths from a few hundreds bases to many kb. The
timeline for generating these two types of models vary
accordingly, as it usually takes only days to synthesize a
ssODN, it takes significantly longer to generate dsDNA
plasmid.
Genotyping of indel, SNP incorporation and small tag
insertions can be accomplished by amplification of the
region encompassing the intended mutation (*500 nt) by
PCR, followed by sequencing, to identify founder mice.
Founders generated by the CRISPR–Cas9 technology often
are mosaic, carrying the NHEJ, HDR as well as any re-
maining wild-type alleles all in one mouse. To identify the
successful HDR alleles among the other events, the mixture
of PCR product should be cloned into a plasmid and in-
dividual clones sequenced to unequivocally confirm the
presence of the HDR allele. For transgene insertion alleles
generated from use of donor plasmid, long range PCR or
Southern blot should be used to examine integrity of the
junction regions between donor homology arms and the
genomic locus. Of particular notice is the possibility of
additional unintended mutations originating from the off-
target effect. These may be screened and if positive,
mitigated by further breeding.
Current challenges and future development
of CRISPR–Cas9
Although CRISPR–Cas9 has been proven powerful and
widely applied, it is still a relatively new technology and
there is much to be understood and improved.
Improving specificity and efficiency of the CRISPR–
Cas9 system
A critical need in CRISPR–Cas9-mediated genome editing
is to minimize the risk of off-target damage. As discussed
above, various strategies can be used to minimize potential
off-target effects, including truncated guide RNA, dual
nickase, dCas9-FokI, etc. However, as each guide sequence
likely has a variable number of off-target sites, ex-
perimental data need to be generated and analyzed to un-
derstand the factors related to off-target effect. With the
use of multiple recently established methods for detecting
off-target mutations and accumulation of data (Frock et al.
2015; Kim et al. 2015; Tsai et al. 2015; Wang et al. 2015),
we can expect more comprehensive models for off-target
prediction based on all the experimental data.
It is known that efficiency of genome editing using site-
specific nucleases varies widely depending on genomic
context. This is thought to result from the combined effects
of different genetic composition and epigenetic state for each



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































M. V. Wiles et al.: CRISPR–Cas9 mediated genome editing and guide RNA design 507
123
particular locus. For example, DNA accessibility has been
correlated with transcription factor binding, and recently
with Cas9 protein binding (Kuscu et al. 2014; Wu et al.
2014). Various histone modifications have been correlated
with transcription factor binding and chromosome structure
(ENCODE Project Consortium et al. 2012; Kundaje et al.
2012; Wang et al. 2012). Due to the complexity of genetic
sequences, epigenetic modifications and different genomic
loci across different cell types, we currently still lack basic
understanding of how the binding, catalytic activity, and
ultimately the efficiency of the CRISPR–Cas9 system is af-
fected. A better understanding of these phenomena will
significantly enhance our ability to efficiently and accurately
target genomic sequences across the genome.
Animal model generation: the challenge of bigger
and faster
One major limitation of current method in developing ge-
netically modified animals is that the founder animals are
often mosaic, carrying more than two alleles with each
appearing at a certain frequency. This is potentially due to
CRISPR–Cas9 activity occurring after the first cell division
of the zygote. A better understanding of cell division and
control of the timing of CRISPR–Cas9 activity, aiming at
modifying the genomic locus strictly at the one cell stage,
may allow creation of homozygote mutant mice that may
be suitable for direct phenotypic analysis without the need
for further breeding. Improvement in this aspect will
shorten the timeline from model creation to phenotypic
analysis. Elimination of mosaicism will be of particular
importance for generating genetically modified large ani-
mals (e.g., non-human primate), which takes years to breed
and often have small liter sizes.
CRISPR–Cas9-mediated genome editing has been used
to generate mouse models carrying mutations in a single or
multiple genes, as well as reporter and conditional alleles
(Wang et al. 2013a; Yang et al. 2013a). However, one of
the most impactful uses of a mouse model is genetic hu-
manization that requires replacement of the mouse gene or
gene cluster with its human ortholog. This is extremely
challenging and time-consuming using gene targeting
method (Lee et al. 2014), and has not been achieved using
CRISPR–Cas9-mediated genome editing. The average size
of a gene is about 50,000 nt and genes from a family can be
localized in a specific genomic locus (for example, the
immunoglobulin gene cluster resides in a region that oc-
cupies a few million nucleotides). Replacement of a few kb
long fragment has been demonstrated in human iPS cells
(Byrne et al. 2015). More needs to be learnt and explored
using the CRISPR–Cas9 system to engineer the genome in
larger scale.
Exploiting the sgRNA backbone to maximize
efficiency and expand utility of the CRISPR–Cas
system
By introducing an A-U flip and extension of the stem loop
structure into the trascrRNA portion of the sgRNA back-
bone, Chen et al. achieved an improved efficiency of gene
repression and genomic loci labeling using the CRISPR–
Cas9 system (Chen et al. 2013). Moreover, different stem
loop structures recognized by RNA binding proteins have
been engineered into the sgRNA backbone, which serve as
a bait to recruit different effectors, for the purpose of gene
activation and repression (Konermann et al. 2014; Zalatan
et al. 2015). By using sgRNAs targeting different genomic
loci, with different effector recruiting stem loops, the same
dCas9 protein could perform different functions at different
target sites, therefore allowing for functional multiplexing
using one CRISPR–Cas9 system (Zalatan et al. 2015).
In addition to DNA target, Cas9 can also bind with high
affinity to single-stranded RNA (ssRNA) targets (O’Con-
nell et al. 2014), although validity of its in vivo application
has yet to be demonstrated. There are orthologous CRISPR
systems that naturally target RNA molecules (Hale et al.
2009, 2012), therefore would be exciting resources to ex-
plore for RNA editing.
Interest in the CRISPR–Cas9 technology as a genome
editing tool has increased exponentially in the last three
years. Since its debut in 2012, there have already been
more than 1000 papers published with CRISPR as the key
word. The collective work from the field has culminated in
the development of many innovative applications and
major breakthroughs have been achieved, including the
establishment of whole genome loss of function and gain of
function screen (Wang et al. 2013b; Konermann et al.
2014; Shalem et al. 2014), as well as the generation of the
first non-human primate knockout model (Niu et al. 2014).
It is tantalizing what the future may hold for the CRISPR–
Cas9 technology, particularly in the area of gene therapy,
but we can be assured that further improvement and de-
velopment of the technology will deliver even greater
achievements.
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